




# Advancing CRISPR Technologies for Therapeutic Application

Christopher Wilson  
TIDES: Oligonucleotide & Peptide Therapeutics  
May 3, 2017



# CRISPR Unlocks Genome Editing

Editing machinery can be engineered to target nearly any genomic location



**Nuclease**



**Guide RNA**

- Complex of nuclease and guide RNA precisely locates and cuts genomic sites
- Ability to target several sites simultaneously using multiple guide RNAs
- Nuclease can be engineered to reach more sites and to modulate cutting

- Reliably manufacture high quality drug substance
- Key understandings:
  - Pharmacokinetics: “what the body does to the drug”
  - Pharmacodynamics: “what the drug does to the body”

## Current Recommendations to Assess Safety of Gene Editing Products




- **Kinetics of nuclease cleavage and persistence of cleavage activity**
- **Percentage of cleavage at the on- and off-target sites**
- **Identification and characterization of off-target events in cells/tissues, including chromosomal translocations**
- **Evaluation of the profile of insertions and deletions and types of mutations generated**

Celia Witten,  
OTAT→CBER→FDA  
Cell and Gene Meeting on the Mesa  
La Jolla, California, October 6, 2016



# Strategy to Widely Enable Efficient Delivery

Success across a spectrum of delivery modalities in preclinical studies




- Tailor delivery approach for each product candidate to match specific disease
- Leverage existing technologies while investing in new approaches



# High Quality Autologous Drug Development

Engineered autologous therapy requires multiple components







# Generating Covalently-Coupled Dual gRNA

A completely non-enzymatic process for guide production

Why make a synthetic guide?


- Targeted chemistries anywhere in the molecule
- Unhindered ends and modifications
- Scale up and purity are more compatible with CMC requirements





# Cellular Editing Activity


In vitro transcribed & synthetic gRNAs are equivalent in cells






# Analytics Demonstrates High Quality Material



A





## Deconvoluted Mass Spectrum



B



Covalently-coupled dual gRNA









# Assessing gRNA purity and sequence fidelity

## Development of an RNA-Seq based method for gRNA QC




NGS library Prep


synthetic 100mer "A"



synthetic 100mer "B"




covalently-coupled dgRNA




# eO | gRNA purity and sequence fidelity

Covalently-coupled dgRNA result in greater sequence fidelity in target region


A



B



Covalently-Coupled dgRNA



- Reliably manufacture high quality drug substance
- Key understandings:
  - Pharmacokinetics: “what the body does to the drug”
  - Pharmacodynamics: “what the drug does to the body”

## Current Recommendations to Assess Safety of Gene Editing Products



- Kinetics of nuclease cleavage and persistence of cleavage activity
- Percentage of cleavage at the on- and off-target sites
- Identification and characterization of off-target events in cells/tissues, including chromosomal translocations
- Evaluation of the profile of insertions and deletions and types of mutations generated


Celia Witten,  
OTAT→CBER→FDA  
Cell and Gene Meeting  
on the Mesa  
La Jolla, California,  
October 6, 2016




# Sensitive Detection of SaCas9 Protein

AlphaLISA protein assay with 2-3 logs linear sensitivity

AlphaLISA standard curve for SaCas9



Dose response in transfected cells







# Sensitive Detection of *S.aureus* gRNAs

Generic gRNA detection assay with 4 logs linear sensitivity

**RT-qPCR for SaCas9 gRNA TRACR  
standard curve**



**Dose response in transfected cells**







# Sensitive and Specific Detection of gRNAs

Multi gRNA edits require specific assays

## Taqman assays are specific for each gRNA



## Expression differences *in vivo* with two gRNAs from a single AAV



- Reliably manufacture high quality drug substance
- Key understandings:
  - Pharmacokinetics: “what the body does to the drug”
  - Pharmacodynamics: “what the drug does to the body”

## Current Recommendations to Assess Safety of Gene Editing Products



- Kinetics of nuclease cleavage and persistence of cleavage activity
- Percentage of cleavage at the on- and off-target sites
- Identification and characterization of off-target events in cells/tissues, including chromosomal translocations
- Evaluation of the profile of insertions and deletions and types of mutations generated

Celia Witten,  
OTAT→CBER→FDA  
Cell and Gene Meeting  
on the Mesa  
La Jolla, California,  
October 6, 2016



# How Do You Best Measure Editing?

A simple question with a complex answer

- PCR based detection approaches are limited to:
  - What is between the primers and
  - Amplicon size
- One cannot detect several events and has to build and “reassemble” answers from disparate technologies (e.g. ddPCR + targeted sequencing):
  - Large Insertions
  - Large deletions
  - Inversions
  - Translocations
- Wanted a size insensitive, multiplex compatible, comparatively easy single tube method that can detect all of the above events





# Single Primer Approaches Achieve Many Goals



While effective, these approaches (HTGTS, AMP-Seq) can be cumbersome

## Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases

Richard L. Frock<sup>1,2,3,4</sup>, Jiazhi Hu<sup>1,2,3,4</sup>, Robin M. Meyers<sup>1,2,3</sup>, Yu-Jui Ho<sup>1,2,3</sup>, Erina Kii<sup>1,2,3</sup>, and Frederick W. Alt<sup>1,2,3,5</sup>

## Anchored multiplex PCR for targeted next-generation sequencing

Zongli Zheng<sup>1,2</sup>, Matthew Liebers<sup>1</sup>, Boryana Zhelyazkova<sup>1</sup>, Yi Cao<sup>1</sup>, Divya Panditi<sup>1</sup>, Kerry D Lynch<sup>1</sup>, Juxiang Chen<sup>1,3</sup>, Hayley E Robinson<sup>1</sup>, Hyo Sup Shim<sup>1,4</sup>, Juliann Chmielecki<sup>5</sup>, William Pao<sup>5</sup>, Jeffrey A Engelman<sup>6</sup>, A John Iafrate<sup>1,6</sup> & Long Phi Le<sup>1,6</sup>




Typically a ½ day Multiple steps

Can induce oxidative DNA Damage (8-oxo-dG)



# Transposase Engineering for Sequencing


Highly efficient and scalable





# Transposase Engineering for Sequencing

Highly efficient and scalable




*10 min single reaction*



# Uni-Directional Targeted Sequencing (UDiTaS)


Blending tagmentation and AMP-seq





# Comparison of Small Indel Measurements

UDiTaS correlates well with targeted sequencing and T7E1 assays





# Intra-Chromosomal Rearrangement Detection

Dual guide edits have multiple possible outcomes



Wildtype



Deletion



Indels (1 or both)



Inversion

Digital Droplet PCR: measures the ratio of 2 qPCR assays on single molecules of genomic DNA




UDiTaS: counts the sequences post junction





# Intra-Chromosomal Rearrangement Detection

Validation using genomic DNA mixing of a stable HEK293T clone

## Stable HEK293 Clone




## Parent HEK293





# Intra-Chromosomal Rearrangement Detection

Follow up experiment defines LLOD (limited by input material and sequencing depth)








# UDiTaS (Uni-Directional Targeted Sequencinging)


A robust method for capturing complex editing events in a single reaction




1. Quantitation of editing



2. Quantitation and discovery of large deletions and inversions



3. Translocation discovery and quantitation



4. Multiplexing

- We can make fully synthetic single gRNAs of high quality
- Pharmacokinetics: high sensitivity and specificity assays measure drug levels
- Pharmacodynamics: UDiTaS is a simple, robust method for capturing complex editing events in a single reaction

Reshica Baral  
Luis Barrera  
Dawn Ciulla  
Cecilia Fernandez  
Ari Friedland  
Georgia Giannoukos  
Sebastian Gloskowski  
Kiran Gogi  
Jenn Gori  
Greg Gotta  
Fred Harbinski

Jack Heath  
Joy Horng  
Hari Jayaram  
Morgan Maeder  
Eugenio Marco  
Rina Mepani  
Andrew Sadowski  
Will Selleck  
Max Skor  
Terence Ta

Bruce Eaton &  
The i2 Pharma team